NGM438 + Pembrolizumab for Cancer

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: NGM Biopharmaceuticals, Inc

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Eligibility Criteria

This trial is for adults with advanced or metastatic solid tumors who have tried all other treatments without success. They should be in good physical condition (able to perform daily activities) and have normal bone marrow, kidney, and liver function. People can't join if they've previously received treatment targeting LAIR1.

Inclusion Criteria

My bone marrow, kidney, and liver are functioning well.

I am fully active or restricted in physically strenuous activity but can do light work.

My side effects from previous treatments are mild or gone.

+2 more

Exclusion Criteria

I have received treatments targeting LAIR1.

Participant Groups

The study is testing NGM438 alone and combined with Pembrolizumab on various cancers like lung, breast, prostate, melanoma, etc., to see how well these treatments work against advanced stages of the diseases.

3Treatment groups

Experimental Treatment

Group I: NGM438 Monotherapy Dose EscalationExperimental Treatment1 Intervention

Part 1a Single Agent Dose Escalation

Group II: NGM438 Combination Dose Finding with pembrolizumab ( KEYTRUDA ® )Experimental Treatment2 Interventions

Part 1b NGM438 plus pembrolizumab ( KEYTRUDA ® )

Group III: Biopsy Cohort with NGM438 Monotherapy Followed by Combination Therapy with Pembrolizumab(KEYTRUDA ®)Experimental Treatment2 Interventions

Part 1C NGM438 followed by NGM438 plus pembrolizumab ( KEYTRUDA ® )